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ABSTRACT
The J-curve effect describes an inverse relation between low blood pressure (BP) and cardiovascular complications. This ef-
fect is more pronounced in patients with preexisting coronary artery disease (CAD), hypertension or left ventricular hyper-
trophy (LVH). The recent large clinical outcomes trials have observed a J-curve effect between a diastolic BP of 70-80 mmHg 
as well as a systolic BP <130 mmHg. The J-curve phenomenon does not appear in stroke or renal disease. This is because the 
coronary arteries are perfused during diastole, but the cerebral and renal perfusion mainly occurs in systole. Therefore, cau-
tion should be taken to maintain the diastolic blood pressure (DBP) at minimum of 70 mmHg and possibly to maintain the 
DBP between 80-85 mmHg in patients with severe LVH, CAD or vascular diseases. BP control in high-risk elderly patients 
should be carefully done as undergoing aggressive therapy to lower the systolic blood pressure below 140 mmHg can cause 
cardiovascular complications due to the severely reduced DBP and increased pulse pressure. (Korean Circ J 2011;41:349-353)
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Introduction
The term “essential hypertension” was first named by Fr-
ank a century ago in 1911, and this was based on his percep-
tion that hypertension is a disease of increased vascular tone 
of the small arteries in the whole body.
1) Thus, an increase in 
blood pressure (BP) is necessary to maintain blood flow to 
target organs through sclerotic arteries. As this notion surviv-
ed into the 1970s, physicians were reluctant to lower BP in the 
elderly patients since they regarded hypertension as being 
compensatory in the aging process.
2) The concept was strong-
ly believed because excessive reduction of blood in some hy-
pertensive emergencies led to organ damage such as renal 
failure, encephalopathy and myocardial ischemia, and the re-
sult was stroke, heart attacks and even death.
3) However, this 
idea gradually changed as treating hypertension showed a 
better prognosis. A large meta-analysis by Lewington et al.
4) 
and that was published in 2002 Lancet about hypertension 
and mortality was comprised of 61 cohort studies targeting 
one million subjects with the support of the British Cardiac 
Society. According to the analysis, vascular mortality in cor-
onary artery disease (CAD) and stroke decreased as the systo-
lic BP decreased from 180 mmHg to 115 mmHg and the dia-
stolic BP declined from 100 mmHg to 75 mmHg. Since then, 
the principle “the lower, the better” has been widely accepted.
 
The J-Curve Concept 
Reports warning against aggressive lowering of BP conti-
nued to exist. This doubt was based on the evidence that a BP 
of 0 mmHg results in 100% mortality. In 1979, after a study 
with over 6 years follow-up, Stewart
5) reported a 5 times high-
er risk of myocardial infarction (MI) in hypertensive patients 
with a diastolic blood pressure (DBP) less than 90 mmHg 
when compared to those with DBP 100-109 mmHg. About 10 
years later, Cruickshank
6) reported a strong J-curve phenome-
non between MI and the DBP in moderate to severe hyper-
tensive patients only when they had CAD. The DBP at the 
nadir of the J-curve ranged from 85 to 90 mmHg and the J-
curve did not appear in the absence of CAD. In several studies 
conducted afterwards, the J-curve in heart attacks and other 
heart diseases was consistently observed whereas no J-curve 350   J-Curve in Hypertension and CAD
was observed in stroke and renal diseases.
7) 
Mechanism of the J-Curve and  
the Pathophysiologic Approach 
Most of the coronary circulation occurs during diastole. Dur-
ing systole, the left ventricular (LV) myocardium contracts 
and compresses the intramyocardial vessels to impede its blo-
od flow. If the diastolic pressure is too low, then the myocar-
dial perfusion can be affected. Thus, the J or U curve hypothe-
sis that a DBP less than 70 or 60 mmHg may cause myocardial 
ischemia and increase mortality is widely accepted. The cor-
onary perfusion pressure is determined by the gradient be-
tween the coronary and LV diastolic pressures. When the co-
ronary perfusion pressure is lowered to 40-50 mmHg, the 
blood flow due to coronary perfusion pressure theoretically 
approaches 0 with exclusion of the LV diastolic pressure.
8) 
The myocardium autoregulates the perfusion pressure in 
the range of 45 to 125 mmHg,
9) and so the myocardium is ca-
pable of enduring various degrees of proximal coronary ste-
nosis. However, in CAD patients, compromised autoregula-
tion reduces the perfusion pressure distal to a stenosis when 
a decrease in the DBP occurs, resulting in an increased LV 
filling pressure. It further decreases the coronary perfusion 
pressure to intensify the vicious cycle of myocardial ischemia. 
As the LVH gets more severe, the LV endocardial ischemia 
worsens and myocardial ischemia occurs even in moderately 
low ranges of DBP.
10)11) 
Reverse causality
Other explanations about the existence of the J-curve have 
been proposed. Reverse causality views coexisting chronic ill-
ness or a poor health condition as a cause for low DBP, which 
leads to increased morbidity and mortality.
12-14) 
According to Established Populations for Epidemiologic 
Studies of the Elderly,
15 17% of the population showed a de-
crease in the systolic blood pressure (SBP) greater than 20 
mmHg and 22% showed a reduction of the DBP more than 
10 mmHg over 3 years. 
The group with reduced DBP showed increased all-cause 
mortality by 1.5 fold, increased cardiovascular mortality by 
1.6 fold and increased cardiovascular events by 1.4 fold. Yet, 
when adjusted for disease and the functional status, there was 
no significant relationship between BP reduction and the haz-
ard ratio. That is, reduced BP in the elderly is a common event 
indicating a poor sanitary status and health condition, and its 
association with increased mortality is an illusion. Such pa-
tients generally have a tendency of both low SBP and low 
DBP; therefore, the PP is not very high. 
Increase in pulse pressure
Low DBP is attributed to progressed vascular disease and 
a rise in the PP due to increased aortic stiffness, and this is not 
the problem itself. In fact, low DBP is related to the J-curve in 
isolated systolic hypertension (ISH) patients, but low DBP is 
not related to the J-curve in patients with low SBP. An exam-
ple is the Systolic Hypertension in the Elderly Program  stu-
dy
16) and the Syst-Eur study
17) on elderly ISH patients, where 
no increase in myocardial ischemia or cardiovascular disease 
(CVD) risk was shown at a DBP of 55-60 mmHg. 
Major Clinical Studies on the J-Curve 
The International Verapamil SR-Trandolapril (INVEST)
study on 22,000 hypertensive patients with CAD compared 
verapamil-based treatment and atenolol based treatment and 
the initial results were reported in 2003. On the analysis of 
the INVEST study by Messerli et al.
18) when considering DBP 
of 80-90 mmHg as the lowest point, DBP below 70-80 mmHg 
shows the J-curve as an increased risk of MI appears (Fig. 1). 
Especially, CAD patients are more sensitive to a reduction in 
DBP and there is 2-fold CAD risk difference between a DBP 
of 80 mmHg and 65 mmHg. The J-curve phenomenon was 
observed in CAD, but not in stroke (Fig. 1). The J-curve effect 
was more apparent in CAD patients who did not go through 
revascularization than those who underwent revasculariza-
Fig. 1. The Incidence of the myocardial infarction and stroke as 
stratified by diastolic blood pressure in the International Verapamil 
SR-Trandolapril study.
18) 
20
15
10
5
0
I
n
c
i
d
e
n
c
e
 
(
%
)
 
o
f
 
M
I
/
s
t
r
o
k
e
≤60        61-70      71-80       81-90     91-100   101-110     >110
MI
Stroke
Fig. 2. Interaction of the J-Curve with coronary revascularization. 
The patients who were revascularized better tolerated a lower di-
astolic blood pressure (DBP) than those who were not.
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tion (Fig. 2). 
In the Randomized Olmesartan And Diabetes MicroAl-
buminuria Prevention study,
19) a SBP below 120 mmHg show-
ed a J-shaped increase of cardiovascular mortality in the ol-
mesartan group compared to the placebo group. The Treating 
to New Targets study
20) was conducted to observe the relation-
ship between antihypertensive treatment and the CAD risk in 
CAD patients. The SBP and DBP were categorized by a 10 
mmHg rise, and the primary end point was set as a major car-
diovascular event such as death from CAD, nonfatal MI, re-
suscitation after cardiac arrest and fatal or nonfatal stroke. Af-
ter a median follow-up of 4.9 years, the lowest BP with the 
lowest incidence of CVD was 146.3/81.4 mmHg. Especially, 
a BP less than 110-120/60-70 mmHg showed the J-curve re-
lationship as the incidence of CVD increased. Yet as SBP de-
creased, the stroke incidence also declined. 
According to the Ontarget study
21) that targeted the high-
risk group, the effect of lowering the SBP was mainly a re-
duction of the incidence of stroke. As the SBP is reduced be-
low 130 mmHg, there was no difference in the MI incidence wh-
ereas there was a J-shaped increase in the CVD mortality.  
Controlling Blood Pressure  
in Diabetes and the J-Curve 
The hypertension optimal treatment (HOT) study,
22) which 
aimed to determine the DBP target in hypertensive patients, 
divided approximately 19,000 patients with essential hyper-
tension and who were 50-80 years old (median age: 61.5) into 
three levels target DBPs (below 80, 80-85 and 85-90 mmHg) 
and then treatment was begun. As a result, the incidence of 
CVD was lower in the lower target DBP groups, with the low-
est incidence for a DBP of 83 mmHg and a SBP of 139 mmHg. 
There was no extra benefit in terms of the cardiovascular event 
even when the DBP was lowered below 90 mmHg in the non-
diabetic patients, but maintaining the DBP below 80 mmHg 
in diabetic patients led to about 50% of extra benefit in reduc-
ing events. In only the smokers, the J-curve was found in the 
group with a target DBP below 80 mmHg as this group show-
ed a 2-fold increase in cardiovascular events compared to the 
group with a target DBP below 90 mmHg. Based on these 
results, the target BP in hypertensive patients with diabetes 
was set as 130/80 mmHg. 
However, this is supported by only a few studies, and specifi-
cally there is no evidence that using anti-hypertensives in the 
patients with BP 130-140/80-90 mmHg offers any extra bene-
fit. The recent data from the Action to Control Cardiovascular 
Risk in Diabetes-blood pressure study,
23) which investigated 
the difference between intensive BP lowering and standard an-
tihypertensive therapy in patients with either diabetes or MI, 
in contrast to the expected outcome, showed no significant 
difference between the intensive BP lowering group with a 
target SBP below 120 mmHg and the standard treatment gr-
oup with a target SBP below 140 mmHg. In addition, a retro-
spective analysis of the INVEST trial to examine the benefit 
of intensive BP control in diabetic patients with CAD reveal-
ed that lowering the BP below 130 mmHg did not offer any 
additional benefit and even the J-curve phenomenon was 
observed as excessive reduction of BP resulted in a higher 
mortality rate (Fig. 3).
Fig. 3. Results of the peoprotion of events in Action to Control Cardiovascular Risk in Diabetes-blood pressure (effects of intensive blood-
pressure control in type 2 diabetes mellitus) (A) and the Adjusted risk of all-cause mortality in International Verapamil SR-Trandolapril (B).
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Studies Contradicting  
the J-Curve Concept 
Reported in 1995, the 16 years of follow-up study of Mul-
tiple Risk Factor Interventional Trial (MRFIT)
24) investigated 
5,440 patients with prior hospitalization of 2 weeks or more 
for MI at the initial screening of MRFIT. In the first 2 years of 
the follow-up, all-cause mortality was high in those patients 
with a SBP <120 mmHg and those with a DBP <70 mmHg. Af-
terwards, the lowest SBP and DBP strata showed a decreasing 
pattern of mortality. If a low DBP is the cause of death, then 
the high mortality rate should have continued for 15 years. 
Therefore, the authors stated that the high mortality is not 
due to a low diastolic pressure, but rather, it was due to a de-
fect in the LV function that led to lower DBP and SBP. It has 
also been suggested that the low DBP results from LV dysfunc-
tion and a reduced stroke volume and this leads to increased 
mortality. 
Glynn et al.
25) followed 22,071 men and 39,876 women in 
the PHS and WHS for a median of 13.0 years and 6.2 years, 
respectively, and they observed an association of the SBP and 
DBP with the risk of MI, stroke, coronary artery bypass, an-
gioplasty and cardiovascular death. In this study, both wom-
en and men with lower SBP had a lower incidence of CVD 
and they did not show the J-curve relationship. There was a 
gender difference in DBP, as a lower DBP reduced CVD with 
a slight J-curve shown below 60 mmHg in men, but there was 
no association or the J-curve relationship between the DBP 
and CVD observed in the women. 
The HOT study, consistent with the study of Cruickshank 
et al.
6) reported a J-shaped relationship between DBP below 
85mmHg and the risk of MI only in the patients with CAD, 
but not in those without CAD. 
According to the Cardiovascular Health Study by Psaty et 
al.
26) the BP level and CVD risk showed a linear relationship 
and the J-curve between DBP and incidence of MI was not 
observed for patients with DBP below 69 mmHg. 
Why Does the J-Curve Appear  
in Coronary Artery Disease, but Not  
in Stroke or Renal Disease? 
Coronary perfusion occurs in diastole, whereas cerebral 
perfusion mainly occurs in systole. Cerebral perfusion is ca-
pable of autoregulation in the range of 40-125 mmHg, so it is 
resistant to low BP. As a result, the J-curve phenomenon does 
not hold true for the incidence of stroke. Renal perfusion also 
occurs mainly in systole, and so no J-curve is observed as well. 
Realistic Approach to  
Manage the J-Curve 
Even today, the J-curve phenomenon in antihypertensive 
therapy is still controversial and there have been only limited 
studies on its relation to SBP. In light of the results from pre-
vious several studies, the occurrence of increased myocardi-
al ischemia resulting from aggressive lowering of the DBP 
should be considered during antihypertensive therapy. Al-
though most of the studies have shown the J-curve for DBP 
below 70-80 mmHg, this phenomenon does not appear in 
stroke or renal disease. Therefore, since the appearance of the 
J-curve in patients with clinically severe LVH, CAD or vascu-
lar diseases is highly probable, caution should be taken to ma-
intain the DBP at minimum of 70 mmHg and possibly to 
maintain the DBP between 80-85 mmHg. 
The SBP is suggested to be controlled according to a rule 
“moderation is the best thing”, rather than the old golden rule 
“the lower the better”. In other words, as 2009 revised Europe-
an Guidelines on Hypertension Management
27) stated, main-
taining a BP of 130-139/80-85 mmHg in patients with hyper-
tension seems to be appropriate using the current evidence-
based medicine (Fig. 4). Since ISH patients already have low 
Fig. 4. The pre- and post-treatment systolic blood pressure clinical benefit in a clinical hypertension study on diabetic patients.
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DBP in many cases and the PP reduction by decreasing the 
SBP has benefits for preventing CVD that outweigh the risks 
caused by a reduced DBP, based on the Syst-Eur study,
17) low-
ering the SBP while maintaining the DBP above 55-60 mmHg 
is suggested if the patients do not have CAD. If they have co-
existing vascular diseases like CAD, then BP control is sug-
gested after reperfusion procedures such as PCI or CABG. A 
careful approach should be used for BP control in high-risk 
elderly patients as undergoing aggressive therapy to lower the 
SBP below 140 mmHg can cause cardiovascular complica-
tions due to the severely reduced DBP and increased PP. 
Conclusion 
The current national and international antihypertensive tr-
eatment guidelines recommend a BP goal of <140/90 mmHg, 
and <130/80 mmHg in patients with CAD, chronic renal 
disease and other CVD. However, the recent large clinical stu-
dies have shown the J-curve phenomenon in patients with a 
DBP <80 mmHg as well as in patients with a SBP <130 
mmHg, and the studies demonstrated no significant differ-
ences in the risk of cardiovascular complications between ag-
gressive antihypertensive therapy and standard therapy. Yet 
the J-shaped curve does not appear for stroke patients, and 
this shows a relationship consistent with the principle “the 
lower the better”.
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